Prof. Franklin L. Rosenfeldt, Baker Heart Research Institute, Alfred Hospital, Monash University, Australia, is known to the readers of the articles on this website. Dr. Rosenfeldt focuses in on the role of Coenzyme Q10 in cardiovascular health and disease. He is interesting because his research has shown the efficacy of supplementation with Coenzyme Q10 in the following situations:
- before and after heart surgery
- in the adjuvant treatment of chronic heart disease
- in the adjuvant treatment of hypertension
- in the protection of the aging heart
In this article, I would like to highlight some of the research results that Professor Rosenfeldt and his team of researchers in Australia have achieved.
Coenzyme Q10 in cardiac surgery
Dr. Rosenfeldt and his team reviewed 8 studies of the use of Coenzyme Q10 supplements with heart surgery patients. 7 of the 8 studies showed beneficial effects of one kind or another. The researchers in the 8th study had used Coenzyme Q10 only 12 hours before surgery, too short a preparation period, in Dr. Rosenfeldt’s opinion, for the Coenzyme Q10 to take effect. Dr. Rosenfeldt and his team have achieved good results by using Coenzyme Q10 for an average of 36 days prior to surgery, and they have continued the Q10 adjuvant treatment following surgery. Their concern has been to prevent or limit the damage of ischemia/reperfusion injury (the heart tissue damage caused by the sudden return of blood to the tissue after a period of less or no blood and oxygen in the tissue).
Please note that Dr. Rosenfeldt’s research results were published in the widely read, by cardiologists and cardiac surgeons, Journal of Thoracic and Cardiovascular Surgery.
Rosenfeldt, F., Marasco, S., Lyon, W., Wowk, M., Sheeran, F., Bailey, M., & … Pepe, S. (2005). Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue. The Journal of Thoracic and Cardiovascular Surgery, 129(1), 25-32.
Coenzyme Q10 in chronic heart failure
Dr. Rosenfeldt was one of the key researchers on the Q-Symbio clinical trial, a randomized, double-blind, placebo-controlled, multi-centre study reported in 2014 in the Journal of the American College of Cardiology specialty journal entitled Heart Failure. He worked closely with Dr. Svend Aage Mortensen, the lead researcher on the Q-Symbio Study.
The Q-Symbio study enrolled 420 patients with severe chronic heart failure (NYHA classes III and IV) from nine countries, including Australia, and gave the patients either 100 mg of Coenzyme Q10 three times a day or corresponding placebo for a period of two years in addition to their conventional medicines.
The Q-Symbio results showed statistically significant reductions in the number of unplanned hospitalizations and in the number of cardiovascular deaths among the patients receiving the active Coenzyme Q10 treatment. The patients receiving the Coenzyme Q10 adjuvant treatment also showed significantly better scores on a biological marker for heart disease called NT-proBNP.
Mortensen, S. A., Rosenfeldt, F., Kumar, A., Dolliner, P., Filipiak, K. J., Pella, D., & … Littarru, G. P. (2014). The effect of Coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC. Heart Failure, 2(6), 641-649.
Coenzyme Q10 in hypertension
Dr. Rosenfeldt and his team reviewed all relevant published study results of the effects of Coenzyme Q10 for hypertension. In all, they analyzed 12 studies enrolling 362 patients with high blood pressure. They concluded that supplementation of hypertensive patients with daily doses of 150 – 300 mg of Coenzyme Q10 could reduce the patients’ systolic blood pressure by as much as 17 mm Hg and could reduce the patients’ diastolic blood pressure by as much as 10 mm Hg without causing any adverse effects.
Rosenfeldt, F. L., Haas, S. J., Krum, H., Hadj, A., Ng, K., Leong, J., & Watts, G. F. (2007). Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension, 21(4), 297-306.
Coenzyme Q10 in the protection of the aging heart
In terms of exercise performance, quality of life, hospitalizations, and recovery from surgery, aging patients are at a disadvantage compared to younger patients. Dr. Rosenfeldt suggests that one big contributing factor to the difference in response based on age is the reduced bio-synthesis of Coenzyme Q10 in elderly people. Coenzyme Q10 is needed in sufficient quantities both for its role in the bio-energetics of the cells and for its role as an antioxidant quenching harmful free radicals.
Rosenfeldt, F. L., Pepe, S., Linnane, A., Nagley, P., Rowland, M., Ou, R., Esmore, D. (2002). Coenzyme Q10 protects the aging heart against stress: studies in rats, human tissues, and patients. Annals of the New York Academy of Sciences, 959355-359.
Conclusions about Coenzyme Q10 supplementation
Based on their own research results and on their reviews of other research into the use of Coenzyme Q10, Dr. Rosenfeldt and his team reach the following conclusions:
- Coenzyme Q10 used as an adjuvant treatment in addition to conventional medical regimes can and does confer significant beneficial health effects on heart failure and hypertension patients.
- We need large-scale randomized controlled trials with respect to Q10 supplementation of ischemic heart disease patients.
- Coenzyme Q10 has been shown to be a safe adjunct treatment for heart disease patients with a much greater upside of therapeutic benefit and practically no downside of side effects. Beyond the occasional report of gastro-intestinal upset, there are no adverse side effects associated with taking a daily dose 150 – 300 mg of Coenzyme Q10.
- 150 – 300 mg daily is the dosage generally needed to raise serum Q10 levels high enough to achieve therapeutic health effects.
Pepe, S., Marasco, S. F., Haas, S. J., Sheeran, F. L., Krum, H., & Rosenfeldt, F. L. (2007). Coenzyme Q10 in cardiovascular disease. Mitochondrion, 7 SupplS154-S167.
Leave A Comment